GNMK News and Press, GenMark Diagnostics Inc. From 02/11/21

CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review th...

Gainers: ESSA Pharma (EPIX) +47%. Ayala Pharmaceuticals (AYLA) +45%. GenMark Diagnostics (GNMK) +27%. ADiTx Therapeutics (ADTX) +27%. Celsion (CLSN) +26%.Losers: Tilray (TLRY) -39%. Anchiano Therapeutics (ANCN) -35%. Zynerba Pharmaceuticals (ZYNE) -28%. Pulmatrix (PULM) -26%. Aphria (APHA) -2...

Gainers: RCM Technologies (RCMT) +85%.Ayala Pharmaceuticals (AYLA) +60%.ESSA Pharma (EPIX) +45%.GenMark Diagnostics (GNMK) +29%.Castor Maritime (CTRM) +28%.Borqs Technologies (BRQS) +26%.SOS Limited (SOS) +25%.Lyra Therapeutics (LYRA) +25%.Inpixon (INPX) +25%.Quotient Technology (QUOT) +...

GenMark Diagnostics (GNMK) may be worth $20-$25/share in a potential sale, Cowen said, after a Bloomberg report that the company is exploring a sale after receiving approaches. Genmark shares jumping 21%.Cowen has always seen GenMark as an attractive target and the company is t...

GenMark Diagnostics (GNMK) is exploring a potential sale after getting interest from potential buyers, according to a Bloomberg report.GenMark is working with an adviser as it garners interest from other medical diagnostics players, Bloomberg said, citing people familiar.Talks are still are a...

GenMark is in the early stages of an accelerated growth phase, backed by the cadence of ePlex instillations, having benefitted from a large Covid-19 tailwind. Management are solid on scaling production to 250K ePlex units by Q3 2021 and are aiming to reach 60% gross profit margins ove...

Gainers: [[VOXX]] +42.9%. [[IRIX]] +22.0%. [[PXLW]] +11.8%. [[QTRX]] +7.9%. [[GNMK]] +6.9%.Losers: [[RDHL]] -9.4%. [[LINC]] -6.1%. [[LMND]] -5.3%. [[APM]] -3.9%. [[REVG]] -3.6%. For further details see: VOXX, IRIX, RDHL and LINC among after-hours movers

GenMark Diagnostics (GNMK) provides preliminary FY revenue to be ~$17M, representing an increase of approximately 95% over 2019.ePlex® revenue for the FY 2020 is expected to be ~$152M, an increase of 155% over 2019.Q4 revenue is expected to be ~$50M, representing an increase of...

CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020. Financial...

It's hard to think of an industry that was more impacted by the 2020 COVID pandemic than diagnostics. The often-overlooked part of the healthcare system sprang into action, testing more than 250 million people last year in the U.S. alone. And interestingly, some testing companies performed ...